AGE-RAGE in Multiple Sclerosis Brain

REFERENCES

• Barnett, M. H., Prineas, J. W. (2004). Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55:458–467.
   PubMed Web of Science ®Google Scholar
• Brownlee, M. (1996). Advanced glycation endproducts in diabetic complications. Curr. Opin. Endocrinol. Diabetes 3:291–297.
   Google Scholar
• Brownlee, M. (1995). Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46:223–234.
   PubMed Web of Science ®Google Scholar
• Bucala, R. (1997). Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis. [Review] Exp. Physiol. 82(2):327–337.
   Google Scholar
• Castellani, R.J., Harris, P.L., (2001). Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 31(2):175–180.
   Google Scholar
• Clynes, R., Moser, B., (2007). Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr. Mol. Med. 7(8):743–751.
   Google Scholar
• Dheen, S. T., Kaur, C., (2007). Microglial activation and its implications in the brain diseases. [Review] Curr. Med. Chem. 14(11):1189–1197.
   PubMed Web of Science ®Google Scholar
• Ding, Q., Keller, J. N. (2005). Evaluation of rage isoforms, ligands, and signaling in the brain. [Review] Biochim. Biophys. Acta 1746(1):18–27.
   Google Scholar
• Drinda, S., Franke, S., (2002). Identification of the advanced glycation end products N(epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann. Rheum. Dis. 61(6):488–492.
   PubMed Web of Science ®Google Scholar
• Emanuele, E., D'Angelo A., (2005). Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62(11):1734–1736.
   Google Scholar
• Ikeda, K., Higashi, T., (1996). N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35(24):8075–8083.
   Google Scholar
• Kislinger, T., Fu, C., (1999). N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274(44):31740–31749.
   PubMed Web of Science ®Google Scholar
• Koonin, E. V., Altschul, S. F., (1996). BRCA1 protein products: functional motifs. Nat. Genet. 13:266–267.
   PubMed Web of Science ®Google Scholar
• Luth, H. J., Ogunlade, V., (2005). Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb. Cortex 15(2):211–220.
   PubMed Web of Science ®Google Scholar
• Onyango, I. G., Tuttle, J. B., (2005). Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol. Cell Neurosci. 29(2):333–343.
   Google Scholar
• Price, C. L., Knight, S. C. (2007). Advanced glycation: a novel outlook on atherosclerosis. [Review] Curr. Pharm. Des. 13(36):3681–3687.
   Google Scholar
• Qin, J., Goswami, R., (2008). Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J. Neurosci. Res. 86(11):2414–2422.
   Google Scholar
• Sakata, N., Imanaga, Y., (1999). Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 142(1):67–77.
   Google Scholar
• Sasaki, N., Toki, S., (2001). Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888(2):256–262.
   Google Scholar
• Sternberg, Z., Weinstock-Guttman, B., (2008). Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult. Scler. 14(6):759–763.
   PubMed Web of Science ®Google Scholar
• Takeuchi, M., Watai, T. (2003). Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 62(5):486–496.
   Google Scholar
• Tanji, N., Markowitz, G. S., (2000). Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11(9):1656–1666.
   PubMed Web of Science ®Google Scholar
• van Horssen, J., Schreibelt, G., (2008). Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Rad. Biol. Med. 45(12):1729–1734.
   PubMed Web of Science ®Google Scholar
• Vlassara, H. (1996). Advanced glycation end-products and atherosclerosis. [Review] Ann. Med. 28(5):419–426.
   Web of Science ®Google Scholar
• Wang, A. L., Yu, A. C., (2007). AGEs mediated expression and secretion of TNF alpha in rat retinal microglia. Exp. Eye Res. 84(5):905–913.
   Google Scholar
• Weiner, H. L. (2009). The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? [Review] Ann. Neurol. 65(3):239–248.
   PubMed Web of Science ®Google Scholar
• Wells-Knecht, K. J., Brinkmann, E., (1996). New biomarkers of Maillard reaction damage to proteins. [Review] Nephrol. Dial Transplant 11 Suppl. 5:41–47.
   PubMedGoogle Scholar
• Yamagishi, S., Nakamura, K., (2008). Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. [Review] Curr. Pharm. Des. 14(5):487–495.
   PubMed Web of Science ®Google Scholar
• Yan, S. D., Bierhaus, A., (2009). RAGE and Alzheimer's disease: A progression factor for amyloid-beta-induced cellular perturbation? [Review] J. Alz. Dis. 16(4):833–843.
   Google Scholar
• Yan, S.S., Wu, Z.Y. (2003). Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat. Med. 9(3):287–293.
   Google Scholar
• Zieman, S. J., Melenovsky, V., (2005). Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25:932–943.
   PubMed Web of Science ®Google Scholar